| |
Progressors
|
Nonprogressors
|
|---|
|
Number of cases
|
14
|
34
|
|
Clinical features
|
|
Age (years)
|
64.6 ± 10.5
|
60.3 ± 10.9
|
|
Gender (M/F)
|
8/6
|
25/9
|
|
Smoking status (N/ES)
|
4/10
|
11/33
|
|
FVC (% e.v.)
|
79.1 ± 21.6
|
76.7 ± 22.8
|
|
DLco (% e.v.)
|
50.2 ± 21.8
|
51.8 ± 7.0
|
|
BALF Lym (%)
|
15.6 ± 14.7
|
36.6 ± 27.6
|
|
Treatment
|
|
Systemic corticosteroids
|
8
|
9
|
|
Supportive care only
|
6
|
0
|
|
Avoidance of inhalation antigen only
|
0
|
25
|
- M Male, F female, N Nonsmoker, ES Ever smoked, FVC Forced vital capacity, DLco Diffusion capacity for carbon monoxide, e.v. expected value
- Definition of progression: significant decline of lung function (10% drop of FVC and/or 15% drop of DLco) or acute exacerbation or death in a 12-month period
